SCHEMBL2539999

SCHEMBL2539999

COc1ccc(-c2cc(CBr)no2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 11/20 0.55
RAB9A P51151 11/20 0.55
HPGD P15428 4/20 0.55
MAPT P10636 3/20 0.55
ALDH1A1 P00352 1/20 0.55
RECQL P46063 1/20 0.55
EPHX2 P34913 1/20 0.50
PTGS2 P35354 1/20 0.50
SMN1; SMN2 Q16637 6/20 0.49
TP53 P04637 3/20 0.49
HTT P42858 1/20 0.48
KMT2A Q03164 2/20 0.47
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4544353 0.85 NPC1 (0.56) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL1754915 0.84 NPC1 (0.55) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL8196656 0.84 NOTUM (0.64) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL29197993 0.81 TDP1 (0.55) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL23813442 0.79 SCD (0.47) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL4060532 0.78 NOTUM (0.70) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL20536341 0.78 NOTUM (0.47) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL2538472 0.78 NOTUM (0.68) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL15009366 0.77 MAPT (0.50) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL6325808 0.77 MAPT (0.62) NPC1RAB9AHPGDMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117417334-A Azole derivative containing isoxazole structure, and preparation method and application thereof 沈阳药科大学 2024-01-19 CN disclosed
EP-1937673-B1 IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA SANOFI SA (FR) 2015-10-21 EP disclosed
US-9150563-B2 Nitrogen-containing aromatic heterocyclyl compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-10-06 US disclosed
US-9150563-B2 Nitrogen-containing aromatic heterocyclyl compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-10-06 US disclosed
US-20140187592-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-07-03 US disclosed
US-20140187592-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-07-03 US disclosed
US-8648103-B2 Nitrogen-containing aromatic heterocyclyl compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-02-11 US disclosed
US-8648103-B2 Nitrogen-containing aromatic heterocyclyl compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-02-11 US disclosed
US-20120108639-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-05-03 US disclosed
US-20120108639-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-05-03 US disclosed
US-8044208-B2 inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor); 3-(6-aminopyridin-3-yl)-2-{1-[5-(5-chlorothiophen-2-yl)isoxazol-3-ylmethyl]-1H-imidazol-4-yl}propionic acid SANOFI-AVENTIS (FR) 2011-10-25 US disclosed
EP-2308838-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND Daiichi Sankyo Company, Limited (JP) 2011-04-13 EP disclosed
US-20080262028-A1 IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
EP-1937673-A1 IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA Sanofi-Aventis (FR) 2008-07-02 EP disclosed
WO-2007045339-A1 IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA SANOFI-AVENTIS (DE) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262028-A1 IMIDAZOLE DERIVATIVES AS INHIBITORS OF TAFIA TFPI, TFPI2, TAF1 NPC1 3430/4885RAB9A 2309/4885HPGD 953/4885
US-20140187592-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND NPR1, NPR3, NPC1 NPC1 3/4885RAB9A 1146/4885HPGD 1638/4885
US-20120108639-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND NPR1, NPR3, NPPA NPC1 8/4885RAB9A 1456/4885HPGD 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.